| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 61 | 2-Substituted-4-substituted-1,3-dioxolanes and use thereof | US09163374 | 1998-09-30 | US06350753B1 | 2002-02-26 | Bernard Belleau; Dilip M. Dixit; Paul Nguyen-Ba |
| Nucleoside analogues containing a 1,3-dioxolane structure are suitable antiviral agents, particulary for the treatment of the HIV infections in mammals, especially humans. Examples of the nucleoside analogues include: cis-2-acetoxymethyl-4-(thymin-1′-yl)-1,3,-dioxolane, cis-2-hydroxymethyl-4-(thymin-1′-yl)-1,3-dioxolane, cis-2-benzoyloxymethyl-4-(cytosin-1′-yl)-1,3-dioxolane, and cis-2-hydroxymethyl-4-(cytosin-1′-yl)-1,3-dioxolane. These compounds can be in the form of their racemates or their separate enantiomers. | ||||||
| 62 | Substituted pyrazolyl-pyrazole derivatives, processes for their preparation and their use as agents with herbicidal action | US148383 | 1998-09-04 | US6028034A | 2000-02-22 | Jens Geisler; Helga Franke; Uwe Hartfiel; Michael Ganzer; Jurgen Bohner; Richard Rees |
| The invention relates to new substituted pyrazol derivatives of general formula (I) in which: R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 have the meanings given in the description, agents with herbicidal action containing at least one compound of formula (I), and their use as herbicides. | ||||||
| 63 | 5-heterocyclic 2-(2-imidazolin-2-yl)-pyridines as herbicides | US36120 | 1993-03-23 | US5283230A | 1994-02-01 | John M. Finn |
| 5-Heterocyclic 2-(2-imidazolin-2-yl)pyridine compounds represented by formulas II and III ##STR1## which are effective for the control of undesirable plant species are described. Also described is a method for the herbicidal use of said compounds. | ||||||
| 64 | 4-(purinyl bases)-substituted-1,3-dioxlanes | US666045 | 1991-03-07 | US5270315A | 1993-12-14 | Bernard Belleau; Dilip Dixit; Nghe Nguyen-Ba |
| There is provided novel 2-substituted-4-substituted-1,3-dioxolanes which are particularly useful as antiviral agents. | ||||||
| 65 | Alkyl esters of 5-heterocyclic-pyridine-2,3-dicarboxylic acids | US714548 | 1991-06-11 | US5239070A | 1993-08-24 | John M. Finn |
| There are provided alkyl esters of 5-heterocyclic-pyridine-2,3-dicarboxylic acids useful as intermediates for the preparation of highly effective 5-heterocyclic-2-(2-imidazolin-2-yl)pyridine herbicidal agents and methods for the preparation thereof. | ||||||
| 66 | Ruthenium-catalyzed production of cyclic sulfates | US369189 | 1989-06-21 | US5112990A | 1992-05-12 | K. Barry Sharpless; Yun Gao |
| A ruthenium catalyzed method to synthesize cyclic sulfate compounds from the corresponding cyclic sulfites, and the cyclic sulfate reaction products obtained by this method. These cyclic sulfates further react with selected nucleophiles to give various substituted products. The method is an efficient means for the synthesis of chiral building blocks from tartaric acid enantiomers in high yields using an overall two-stage, one-pot reaction procedure. The chiral compounds can be transformed by nucleophilic reactions into chiral building blocks useful for the synthesis of natural biologically active products, such as antibiotics and pheromones. | ||||||
| 67 | 5-heterocyclic 2-(2-imidazolin-2-yl)pyridines, useful as herbicidal agents | US457606 | 1989-12-27 | US5039333A | 1991-08-13 | John M. Finn |
| 5-Heterocyclic 2-(2-imidazolin-2-yl)pyridine compounds which are effective for the control of undesirable plant species are described. Also described are a method for the herbicidal use of said compounds and a method for their preparation. | ||||||
| 68 | Alkyl esters of 5-heterocyclic-pyridine-2,3-dicarboxylic acids | US457607 | 1989-12-27 | US5026859A | 1991-06-25 | John M. Finn |
| There are provided alkyl esters of 5-heterocyclic-pyridine-2,3-dicarboxylic acids useful as intermediates for the preparation of highly effective 5-heterocyclic-2-(2-imidazolin-2-yl)pyridine herbicidal agents and methods for the preparation thereof. | ||||||
| 69 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | US16326189 | 2017-08-15 | US20190185456A1 | 2019-06-20 | Qingyun REN; Changhua TANG; Junjun YIN; Kai YI; Yingjun ZHANG |
| The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza. | ||||||
| 70 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | US16094536 | 2017-05-09 | US20190127351A1 | 2019-05-02 | John F. KADOW; B. Narasimhulu NAIDU; Manoj PATEL; Michael A. WALKER; Tao WANG; Zhiwei YIN; Zhongxing ZHANG; Zhizhen Barbara ZHENG |
| Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS. | ||||||
| 71 | SUBSTITUTED IMIDAZOLYLCARBOXAMIDES AS PESTICIDES | US16076667 | 2017-02-03 | US20190045783A1 | 2019-02-14 | Markus HEIL; Reiner FISCHER; Johannes-Rudolf JANSEN; Matthieu WILLOT; Susanne KÜBBELER; David WILCKE; Kerstin ILG; Peter LÕSEL; Sascha EILMUS; Wolfram ANDERSCH; Daniela PORTZ; Ulrich GÕRGENS |
| The present invention relates to compounds of the general formula (I) in which Q, V, T, W, X, Y and A have the meanings given in the description—and to their use for controlling animal pests. | ||||||
| 72 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | US16031357 | 2018-07-10 | US20180319772A1 | 2018-11-08 | Kevin Sprott; Jason J. Marineau; Darby Schmidt; Michael Bradley; Stephane Ciblat; M. Arshad Siddiqui; Anzhelika Kabro; Melissa Leblanc; Serge Leger; Stephanie Roy; Dana K. Winter; Tom Miller; Amy Ripka; Dansu Li |
| The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject. | ||||||
| 73 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | US15799661 | 2017-10-31 | US10059690B2 | 2018-08-28 | Stephane Ciblat; Kevin Sprott; Dana K. Winter; Amy Ripka; Dansu Li; Michael Bradley; Anzhelika Kabro; Melissa Leblanc; Serge Leger; Jason J. Marineau; Tom Miller; Stephanie Roy; Darby Schmidt; M. Arshad Siddiqui |
| The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject. | ||||||
| 74 | Organic Electroluminescent Materials and Devices | US15483032 | 2017-04-10 | US20180108844A1 | 2018-04-19 | Chi Hang Lee; Raymond Kwong |
| The present invention includes fused tetraphenylene compounds that may be used as charge transporters, hosts or emitters in OLEDs. | ||||||
| 75 | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent | US15698020 | 2017-09-07 | US09938243B2 | 2018-04-10 | Peter Kumpalume; Oliver Schon; Christine Patricia Donahue; Ghotas Evindar; David I. Israel; David Paolella; Letian Kuai; Ninad V. Prabhu |
| Compounds useful for affinity chromatography as presented, more particularly for use in affinity chromatography to purify serum albumin, especially human serum albumin (HSA) and fusion proteins thereof. Methods for extending the half-life of therapeutic agents are also presented, particularly therapeutic peptide agents and small molecules, such as by conjugation of compounds described herein to the therapeutic peptide or small molecule, which, upon administration, binds to HSA, thereby providing a prolonged release of the therapeutic agent. | ||||||
| 76 | AGONISTS OF THE MU OPIOID RECEPTOR | US15498725 | 2017-04-27 | US20170313692A1 | 2017-11-02 | Thomas E. Prisinzano; Andrew P. Riley; Chad E. Groer |
| The present technology is directed to compounds, compositions, and methods related to non-morphinan-like mu opioid receptor agonists. Compounds of the present technology demonstrate remarkable potency and selectivity for the mu opioid receptor over the kappa opioid receptor, while also exhibiting a significant reduction (or, essentially, absence) of the negative side effects of many morphine-derived compounds. | ||||||
| 77 | 6-acyl-1,2,4-triazine-3,5-dione derivative and herbicides | US14603029 | 2015-01-22 | US09573909B2 | 2017-02-21 | Atsushi Shibayama; Ryu Kajiki; Masami Kobayashi; Takashi Mitsunari; Atsushi Nagamatsu |
| Disclosed are triazine derivative compounds exhibiting sufficient herbicidal activity at low application dosage when they are applied to soils and foliage, and an agrochemical composition using the same, in particular herbicides. | ||||||
| 78 | Heterocyclic compounds and uses thereof | US14297526 | 2014-06-05 | US09546180B2 | 2017-01-17 | Alfredo C. Castro; Catherine A. Evans; Somarajannair Janardanannair; Andre Lescarbeau; Tao Liu; Daniel A. Snyder; Martin R. Tremblay; Pingda Ren; Yi Liu; Liansheng Li; Katrina Chan |
| Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein. | ||||||
| 79 | CONJUGATED COMPOUND HAVING PHENOXATHIINL, METHOD FOR PREPARING THE SAME AND OLED DEVICE | US14763827 | 2015-05-22 | US20160322584A1 | 2016-11-03 | Xianjie Li; Yuanchun Wu; Shijian Su; Ming Liu; Kunkun Liu |
| The disclosure provides a conjugated compound having phenoxathiinl, method for preparing the same and OLED. The conjugated compound has one of the following formulas: Different kinds of electron-rich conjugated aromatic units are reacted with intermediate having phenoxathiinl by Suzuki coupling, Buchwald-Hartwig coupling, or Cu-catalyzed amination of halogenated aromatic hydrocarbons for forming the conjugated compound having phenoxathiin. The prepared novel compound is fluorescent, so that it can be used as the material of light emitting layer of OLED devices. | ||||||
| 80 | CYANOTRIAZOLE COMPOUNDS | US14905310 | 2014-07-16 | US20160229816A1 | 2016-08-11 | Seiji SATO; Satoshi MATSUDA; Chiharu MATSUMURA; Motohire ITOTANI; Toshio SHINOHARA; Shigekazu FUJITA; Yohji SAKURAI; Kuninori TAI; Tae FUKUSHIMA; Naohide KANEMOTO; Takashi OKAMOTO |
| This invention relates to a cyanotriazole compound represented by the formula (1): wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure. | ||||||
QQ群二维码
意见反馈
意见反馈